Find it in seconds.
Sectors Tags Blog
ABBV
37 filings
Timeline Columns Start Research 8-K Categories
2025
Q4 3 filings
Nov 4
Q3 2025 Results
Unable to extract specific revenue and EPS figures from provided XBRL metadata
10-Q View →
Oct 31
Q3 2025 Earnings Released
Revenue and Financial Results for Q3 2025
8-K View →
Oct 3
Q3 Guidance Update
$2.7B IPR&D expense, EPS guidance $10.38-$10.58
8-K View →
Q3 4 filings
Sep 11
RINVOQ Patent Settlement
No generic entry expected until April 2037
8-K View →
Aug 4
Q2 2025 Results
Unable to extract specific revenue and EPS figures from provided data
10-Q View →
Jul 31
Q2 Earnings
Q2 2025 financial results announced
8-K View →
Jul 3
Q2 2025 Guidance Update
Full-year EPS guidance $11.67-$11.87, Q2 EPS guidance $2.84-$2.88
8-K View →
Q2 4 filings
May 13
Annual Meeting & Board Changes
Thomas J. Falk appointed director, board size 15→13 after July retirements
8-K View →
May 9
Q1 2025 Results
Unable to extract revenue and EPS data from provided filing content
10-Q View →
Apr 25
Q1 Earnings
Q1 2025 financial results for quarter ended March 31, 2025
8-K View →
Apr 3
Q1 2025 Guidance Update
FY 2025 adj EPS guidance $11.99-$12.19, Q1 adj EPS $2.34-$2.38
8-K View →
Q1 9 filings
Mar 24
2025 Proxy Statement
Annual Meeting: May 9, 2025, Virtual format, Record date: March 10, 2025
DEF 14A View →
Feb 26
Debt Offering
$4B notes issued: 4.65% 2028, 4.875% 2030, 5.2% 2035, 5.6% 2055
8-K View →
Feb 19
Debt Offering
$4B multi-tranche notes offering: $1.25B 2028s at 4.65%, $1B 2030s at 4.875%, $1B 2035s at 5.20%, $750M 2055s at 5.60%
8-K View →
Feb 14
Chairman Succession
Robert A. Michael to succeed Richard A. Gonzalez as Chairman effective July 1, 2025
8-K View →
Feb 14
FY2024 Results
Unable to extract specific revenue and EPS figures from provided XBRL taxonomy data
📌 Completed acquisition of Cerevel Therapeutics in August 2024 and ImmunoGen in February 2024, expanding neuroscience and oncology portfolios
10-K View →
Feb 5
New Revolving Credit Facility
$3B unsecured revolver, 5-year term, total facilities now $8B
8-K View →
Jan 31
Q4 2024 Earnings
Financial results for Q4 and full year ended Dec 31, 2024
8-K View →
Jan 10
Material Impairment Charge
$3.5B non-cash after-tax impairment on emraclidine asset
8-K View →
Jan 6
Q4 2024 Guidance Update
Q4 EPS guidance $2.06-$2.10, FY2024 EPS guidance $10.02-$10.06 including $1.6B IPR&D expense
8-K View →
2024
Q4 4 filings
Dec 13
Controller Transition
Kevin Buckbee retiring March 1, 2025; David Purdue appointed at $550K base
8-K View →
Nov 4
Q3 2024 Results
Unable to extract revenue and EPS from provided content
10-Q View →
Oct 30
Q3 2024 Earnings
Q3 2024 financial results announced
8-K View →
Oct 3
Q3 2024 Guidance Update
Full-year EPS guidance $10.67-$10.87, Q3 EPS guidance $2.88-$2.92
8-K View →
Q3 4 filings
Sep 10
Bylaws Amendment
Updated registered agent address, deleted section 2.13(D)(iv) due to stockholder lawsuit
8-K View →
Aug 7
Q2 2024 Results
Unable to extract specific revenue and EPS figures from provided XBRL tags
10-Q View →
Jul 25
Q2 2024 Earnings
Q2 2024 financial results announced
8-K View →
Jul 3
Q2 2024 Guidance Update
Full-year EPS guidance $10.61-$10.81, Q2 EPS guidance $2.53-$2.57 including $937M IPR&D expense
8-K View →
Q2 3 filings
May 3
Q1 2024 Results
Unable to extract specific revenue and EPS figures from provided XBRL data
10-Q View →
Apr 26
Q1 2024 Earnings
Q1 2024 financial results announced
8-K View →
Apr 3
Current Report
8-K View →
Q1 6 filings
Feb 26
Current Report
8-K View →
Feb 20
Current Report
8-K View →
Feb 20
Annual Report
10-K View →
Feb 12
Current Report
8-K View →
Feb 2
Current Report
8-K View →
Jan 5
Current Report
8-K View →
SECENDS is not affiliated with the SEC. Data from public EDGAR filings. Not financial advice.